Thyroid CancerNCT03624751
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
An observational study of Thyroid Cancer, run by Taichung Veterans General Hospital at 1 site in Taiwan.
Trial summary
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thyroid Cancer
- What is being tested?
- radioiodine
- Type of treatment
- Injection or infusion, Surgery or procedure
- How many people
- 107 participants
- Where
- 1 siteTaiwan
- Study dates
- 6 Jun 2018to 30 Jun 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with diagnosis of thyroid cancer
Who may be able to join
- Patients with diagnosis of thyroid cancer。
- Patients who need radioiodine therapy or scan。
Who cannot join
- Patients cannot cooperate with blood test.。
- Patients cannot cooperate with radioiodine therapy。
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
Taichung, 407
About this study
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Read the detailed description
- Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile.
- Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Inclusion ： Patient number: 500人
Inclusion criteria :
- Patients with diagnosis of thyroid cancer。
- Patients who need radioiodine therapy or scan。
Exclusion criteria:
- Patients cannot cooperate with blood test.。
- Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。
Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.
- Conditions
- Thyroid Cancer
- Being tested
- radioiodine
- Medical subject headings
- Thyroid Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
radioiodineRadiation
Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
What is being measured
The primary outcome is the main question the study is designed to answer.
Zung's Self-reported depression scale
Depression symtpoms
Measured: 1 month
Secondary outcomes (7)
Brain-derived neurotrophic factor
BDNF
Measured: 1 month
orexin
An associated factor for depression
Measured: 1 month
Body composition
Fat component percentage to lean mass percentage ratio
Measured: 1 months
VCAM-1
adhesion molecules
Measured: 1 months
CRP
inflammation marker
Measured: 1 months
Metabolic syndrome
The number of conponents for metabolic syndrome
Measured: 1 months
Insulin resistance
HOMA-IR
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2018
- Study start6 Jun 2018
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- More trials run by Taichung Veterans General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 107 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Taichung Veterans General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03624751
- Sponsor's protocol ID
- CE18104A
- Status last verified
- Apr 2026
- First submitted
- 24 May 2018
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
- ClinicalTrials.gov ID
- NCT03624751
- Acronym / sponsor ID
- CE18104A
- Conditions
- Thyroid Cancer
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 107 participants (estimated)
- Lead sponsor
- Taichung Veterans General HospitalUniversity, hospital or other
- Study start
- 6 Jun 2018 (actual)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2030 (estimated)
- First posted
- 10 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Detailed description
- Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile.
- Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Inclusion ： Patient number: 500人
Inclusion criteria :
- Patients with diagnosis of thyroid cancer。
- Patients who need radioiodine therapy or scan。
Exclusion criteria:
- Patients cannot cooperate with blood test.。
- Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。
Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with diagnosis of thyroid cancer
Key inclusion criteria (2 listed)
- Patients with diagnosis of thyroid cancer。
- Patients who need radioiodine therapy or scan。
Key exclusion criteria (2 listed)
- Patients cannot cooperate with blood test.。
- Patients cannot cooperate with radioiodine therapy。
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| radioiodinePatients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. | Radiation | – |
Primary outcome
Zung's Self-reported depression scale
Time frame: 1 month
Depression symtpoms
7 secondary outcomes
Brain-derived neurotrophic factor
Time frame: 1 month
orexin
Time frame: 1 month
Body composition
Time frame: 1 months
VCAM-1
Time frame: 1 months
CRP
Time frame: 1 months
Metabolic syndrome
Time frame: 1 months
Insulin resistance
Time frame: 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Thyroid Cancer
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Recruiting
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Thyroid Gland Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancer, run by Taichung Veterans General Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Zung's Self-reported depression scale (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.